Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Gening Jiang, Hezhong Chen et al.|Signal Transduction and Targeted Therapy|2024Cited by 30
Significantly enhancing human antibody affinity via deep learning and computational biology-guided single-point mutationsJunxin Li, Haiping Zhang, Qiuliyang Yu et al.|Briefings in Bioinformatics|2025Cited by 3